<SEC-DOCUMENT>0001193125-21-349137.txt : 20211206
<SEC-HEADER>0001193125-21-349137.hdr.sgml : 20211206
<ACCEPTANCE-DATETIME>20211206171605
ACCESSION NUMBER:		0001193125-21-349137
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211206
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211206
DATE AS OF CHANGE:		20211206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACADIA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001070494
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				061376651
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50768
		FILM NUMBER:		211473897

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-558-2871

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d257158d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:acad="http://www.acadia-pharm.com/20211206" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2021-12-06_to_2021-12-06">ACADIA PHARMACEUTICALS INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-12-06_to_2021-12-06">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-12-06_to_2021-12-06">0001070494</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="acad-20211206.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-12-06_to_2021-12-06"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001070494</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-06</xbrli:startDate> <xbrli:endDate>2021-12-06</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-12-06_to_2021-12-06">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-12-06_to_2021-12-06" format="ixt:datemonthdayyearen">December 6, 2021</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Acadia Pharmaceuticals Inc.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-12-06_to_2021-12-06" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-12-06_to_2021-12-06">000-50768</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-12-06_to_2021-12-06">06-1376651</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-12-06_to_2021-12-06">12830 El Camino Real</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2021-12-06_to_2021-12-06">Suite 400</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-12-06_to_2021-12-06">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-12-06_to_2021-12-06" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-12-06_to_2021-12-06">92130</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-12-06_to_2021-12-06">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-12-06_to_2021-12-06">558-2871</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form <span style="white-space:nowrap">8-K):</span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-12-06_to_2021-12-06" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-12-06_to_2021-12-06" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-12-06_to_2021-12-06" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-12-06_to_2021-12-06" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-06_to_2021-12-06">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-06_to_2021-12-06">ACAD</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-06_to_2021-12-06" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-12-06_to_2021-12-06" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;6, 2021, the Company announced positive <span style="white-space:nowrap">top-line</span> results from Lavender<sup style="font-size:85%; vertical-align:top">&#8482;</sup>, its pivotal, Phase 3 study of trofinetide in Rett syndrome. Lavender<sup style="font-size:85%; vertical-align:top">&#8482;</sup> was a <span style="white-space:nowrap">12-week,</span> double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged <span style="white-space:nowrap">5-20</span> years with Rett syndrome. The study demonstrated a statistically significant improvement over placebo for both <span style="white-space:nowrap">co-primary</span> endpoints. On the Rett Syndrome Behaviour Questionnaire (RSBQ), change from baseline to week 12 was <span style="white-space:nowrap">-5.1</span> vs. <span style="white-space:nowrap">-1.7</span> (p=0.0175; effect size = 0.37). The Clinical Global Impression&#8211;Improvement <span style="white-space:nowrap">(CGI-I)</span> score at week 12 was 3.5 vs. 3.8 (p=0.0030; effect size = 0.47). The RSBQ is a caregiver assessment of the core symptoms of Rett syndrome and the <span style="white-space:nowrap">CGI-I</span> is a global physician assessment of worsening or improving of Rett syndrome. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, trofinetide demonstrated a statistically significant separation over placebo on the key secondary endpoint, the Communication and Symbolic Behavior Scales Developmental Profile<sup style="font-size:85%; vertical-align:top">&#8482;</sup> Infant-Toddler Checklist&#8211;Social composite score <span style="white-space:nowrap"><span style="white-space:nowrap">(CSBS-DP-IT&#8211;Social)</span></span> change from baseline to week 12 <span style="white-space:nowrap">(-0.1</span> vs. <span style="white-space:nowrap">-1.1;</span> p=0.0064; effect size = 0.43). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Study treatment discontinuation rates related to treatment emergent adverse events (TEAEs) were 17.2% in the trofinetide group as compared to 2.1% in the placebo group. The most common adverse events were diarrhea (80.6% with trofinetide vs. 19.1% with placebo), of which 97.3% in the trofinetide arm were characterized as <span style="white-space:nowrap"><span style="white-space:nowrap">mild-to-moderate,</span></span> and vomiting (26.9% with trofinetide vs. 9.6% with placebo), of which 96% in the trofinetide arm were characterized as <span style="white-space:nowrap"><span style="white-space:nowrap">mild-to-moderate.</span></span> Serious adverse events were observed in 3.2% of study participants in both the trofinetide and placebo groups. Patients completing the Lavender study had the opportunity to continue to receive trofinetide in the open-label Lilac and <span style="white-space:nowrap">Lilac-2</span> extension studies. More than 95% of participants who completed the Lavender study elected to roll-over to the Lilac open-label extension study. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acadia is planning for a <span style="white-space:nowrap">pre-NDA</span> meeting with the U.S. Food and Drug Administration (FDA) in the first quarter of 2022 and plans to submit a new drug application (NDA) around <span style="white-space:nowrap">mid-year</span> 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of ACADIA&#8217;s press release issued December&#160;6, 2021 is furnished herewith as Exhibit 99.1. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this Current Report that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to: intended activities with respect to the Lavender study and the Company&#8217;s planned engagement with the FDA. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to the Company&#8217;s annual report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2020 as well as its subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d257158dex991.htm">Press Release dated December 6, 2021 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Acadia Pharmaceuticals Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dated: December&#160;6, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Austin D. Kim</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Austin D. Kim</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Executive Vice President, General Counsel&#160;&amp; Secretary</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d257158dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g257158g01j23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Acadia Pharmaceuticals Announces Positive <FONT STYLE="white-space:nowrap">Top-line</FONT> Results from
the Pivotal Phase 3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lavender Trial of Trofinetide in Rett Syndrome </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Trofinetide met <FONT STYLE="white-space:nowrap">co-primary</FONT> efficacy endpoints demonstrating statistically significant improvement
over placebo in the Rett Syndrome Behaviour Questionnaire (RSBQ) (p=0.0175) and the Clinical Global Impression of Improvement <FONT STYLE="white-space:nowrap">(CGI-I)</FONT> (p=0.0030) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Trofinetide met key secondary endpoint demonstrating statistically significant improvement over placebo in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CSBS-DP-IT</FONT></FONT></I>&#150;<I>Social (p=0.0064), caregiver scale of ability to communicate </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- <FONT STYLE="white-space:nowrap">Pre-New</FONT> Drug Application meeting with the U.S. FDA planned for the first quarter 2022 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Conference call and webcast to be held today at 4:30 p.m. Eastern Time </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAN DIEGO &#151; December&nbsp;6, 2021 &#150;</B> Acadia Pharmaceuticals Inc.&nbsp;(Nasdaq: ACAD) today announced positive
<FONT STYLE="white-space:nowrap">top-line</FONT> results from the pivotal, Phase 3 Lavender<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>study evaluating the efficacy and safety of
trofinetide in 187 girls and young women aged <FONT STYLE="white-space:nowrap">5-20</FONT> years with Rett syndrome. The <FONT STYLE="white-space:nowrap">12-week</FONT> placebo-controlled study demonstrated a statistically significant improvement
over placebo for both <FONT STYLE="white-space:nowrap">co-primary</FONT> endpoints. On the Rett Syndrome Behaviour Questionnaire (RSBQ), change from baseline to week 12 was <FONT STYLE="white-space:nowrap">-5.1</FONT> vs. <FONT
STYLE="white-space:nowrap">-1.7</FONT> (p=0.0175; effect size=0.37). The Clinical Global Impression&#150;Improvement <FONT STYLE="white-space:nowrap">(CGI-I)</FONT> score at week 12 was 3.5 vs. 3.8 (p=0.0030; effect size=0.47). The RSBQ is a
caregiver assessment of the core symptoms of Rett syndrome and the <FONT STYLE="white-space:nowrap">CGI-I</FONT> is a global physician assessment of worsening or improving of Rett syndrome. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, trofinetide demonstrated a statistically significant separation over placebo on the key secondary endpoint, the Communication and Symbolic
Behavior Scales Developmental Profile<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> Infant-Toddler Checklist&#150;Social composite score
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(CSBS-DP-IT&#150;Social)</FONT></FONT> change from baseline to week 12 was <FONT STYLE="white-space:nowrap">-0.1</FONT> vs. <FONT STYLE="white-space:nowrap">-1.1</FONT> (p=0.0064;
effect size=0.43). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;These are encouraging results for patients and families affected by Rett syndrome. Patients reported improvements in core
symptoms, like being able to respond to a choice when asked by their parents, or experiencing more freedom from the repetitive hand movements that create obstacles in other areas of their lives,&#148; said Jeffrey L. Neul, M.D., Ph.D., Annette
Schaffer Eskind Chair and Director, Vanderbilt Kennedy Center; Professor of Pediatrics, Division of Neurology, Pharmacology, and Special Education, Vanderbilt University Medical Center and Lavender study investigator. &#147;The positive Lavender
study results support a potential treatment for Rett syndrome and represent an important step forward in addressing this rare and serious neurological disease.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Study treatment discontinuation rates related to treatment emergent adverse events (TEAEs) were 17.2% in the trofinetide group as compared to 2.1% in the
placebo group. The most common adverse events were diarrhea (80.6% with trofinetide vs. 19.1% with placebo), of which 97.3% in the trofinetide arm were characterized as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mild-to-moderate,</FONT></FONT> and vomiting (26.9% with trofinetide vs. 9.6% with placebo), of which 96% in the trofinetide arm were characterized as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mild-to-moderate.</FONT></FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Serious adverse events were observed in 3.2% of study participants in both the trofinetide and placebo groups. Patients completing the Lavender study had the opportunity to continue to receive
trofinetide in the open-label Lilac and <FONT STYLE="white-space:nowrap">Lilac-2</FONT> extension studies. More than 95% of participants who completed the Lavender study elected to roll-over to the Lilac open-label extension study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results from this study will be submitted for presentation at upcoming medical meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The consistent efficacy across primary and key secondary endpoints in the Lavender study demonstrates the potential of trofinetide to treat Rett
syndrome,&#148; said Kathie Bishop, Ph.D., Acadia&#146;s Senior Vice President, Chief Scientific Officer and Head of Rare Disease. &#147;We want to thank the patients, their caregivers, study site personnel, physicians and everyone who participated
in the Lavender study for their contribution to making this milestone a reality. We look forward to continuing this important work and potentially delivering an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> treatment for this rare and
devastating disease.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acadia is preparing for a <FONT STYLE="white-space:nowrap">pre-NDA</FONT> meeting with the U.S. Food and Drug Administration
(FDA) in the first quarter of 2022 and plans to submit a New Drug Application (NDA) around <FONT STYLE="white-space:nowrap">mid-year</FONT> 2022. Trofinetide has been granted Fast Track Status and Orphan Drug Designation for Rett syndrome.
Trofinetide has also been granted Rare Pediatric Disease (RPD) designation by the FDA. An NDA with Orphan Drug Designation is eligible for priority review. With an RPD NDA we would expect to be awarded a Priority Review Voucher if approved, subject
to final determination by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2018, Acadia entered into an exclusive license agreement with Neuren Pharmaceuticals Limited (ASX: NEU) for the
development and commercialization of trofinetide for Rett syndrome and other indications in North America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conference Call and Webcast Information
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acadia will discuss <FONT STYLE="white-space:nowrap">top-line</FONT> results from its Lavender study of trofinetide for the treatment of Rett syndrome
via conference call and webcast today at 4:30 p.m. Eastern Time. The conference call can be accessed by dialing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">855-638-4820</FONT></FONT> for participants in the U.S. or Canada and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">443-877-4067</FONT></FONT> for international callers (reference passcode 7989366). A telephone replay of the conference call may be accessed through December&nbsp;20, 2021 by dialing <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">855-859-2056</FONT></FONT> for callers in the U.S. or Canada and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">404-537-3406</FONT></FONT> for international callers
(reference passcode 7989366). The conference call will also be webcast live on Acadia&#146;s website, www.acadia-pharm.com, in the investors section and archived until January&nbsp;3, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About Lavender</I><SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lavender study was a Phase 3, <FONT STYLE="white-space:nowrap">12-week,</FONT> double-blind, randomized, placebo-controlled study of trofinetide in 187
girls and young women aged <FONT STYLE="white-space:nowrap">5-20</FONT> years with Rett syndrome, designed to evaluate its efficacy and safety. The <FONT STYLE="white-space:nowrap">co-primary</FONT> endpoints of Lavender included both a caregiver
(Rett Syndrome Behaviour Questionnaire [RSBQ]) and physician (Clinical Global Impression&#150;Improvement <FONT STYLE="white-space:nowrap">[CGI-I])</FONT> assessment. The key secondary endpoint was also a caregiver assessment designed to evaluate
communication skills, the Communication and Symbolic Behavior Scales Developmental Profile<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> <FONT STYLE="white-space:nowrap">Infant-Toddler</FONT> Checklist &#150; Social Composite Score <FONT
STYLE="white-space:nowrap">(CSBS-DP-</FONT> IT&#150;Social). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About Rett Syndrome </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rett syndrome is a rare, debilitating neurological disorder that occurs primarily in females following apparently normal development for the first six months
of life. Rett syndrome is often misdiagnosed as autism, cerebral palsy, or <FONT STYLE="white-space:nowrap">non-specific</FONT> developmental delay. Rett syndrome is caused by mutations on the X chromosome on a gene called <I>MECP2</I>. There are
more than 200 different mutations found on the <I>MECP2</I> gene that interfere with its ability to generate a normal gene product. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rett syndrome occurs worldwide in approximately one of every 10,000 to 15,000 female births and in the
United States impacts 6,000 to 9,000 patients. Rett syndrome causes problems in brain function that are responsible for cognitive, sensory, emotional, motor and autonomic function. Typically, with symptoms presenting between six to 18 months of age,
patients experience a period of rapid decline with loss of purposeful hand use (fine motor skills), development of hand stereotypies, absent or impaired mobility (gross motor skills), loss of communication skills (including eye contact) and
inability to independently conduct activities of daily living. Symptoms also include seizures, disorganized breathing patterns, an abnormal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">side-to-side</FONT></FONT> curvature of the
spine (scoliosis), and sleep disturbances. Currently, there are no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> medicines for the treatment of Rett syndrome. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About Trofinetide </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trofinetide is an investigational
drug. It is a novel synthetic analog of the <FONT STYLE="white-space:nowrap">amino-terminal</FONT> tripeptide of <FONT STYLE="white-space:nowrap">IGF-1</FONT> designed to treat the core symptoms of Rett syndrome by potentially reducing
neuroinflammation and supporting synaptic function. Trofinetide is thought to stimulate synaptic maturation and overcome the synaptic and neuronal immaturities that are characteristic of Rett syndrome pathophysiology. In the central nervous system, <FONT
STYLE="white-space:nowrap">IGF-1</FONT> is produced by both of the major types of brain cells &#150; neurons and glia. <FONT STYLE="white-space:nowrap">IGF-1</FONT> in the brain is critical for both normal development and for response to injury and
disease. Trofinetide has been shown to inhibit the production of inflammatory cytokines, inhibit the overactivation of microglia and astrocytes, and increase the amount of available <FONT STYLE="white-space:nowrap">IGF-1</FONT> that can bind to <FONT
STYLE="white-space:nowrap">IGF-1</FONT> receptors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trofinetide has been granted Fast Track Status and Orphan Drug Designation for Rett syndrome.
Trofinetide has also been granted Rare Pediatric Disease (RPD) designation by the FDA. Upon FDA approval of a product with RPD designation, the sponsor can receive a Priority Review Voucher, which can be used to obtain FDA review of a New Drug
Application for another product in an expedited period of six months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About&nbsp;Acadia Pharmaceuticals</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital
solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson&#146;s disease psychosis. Our late-stage development efforts are focused on
dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system
disorders. For more information, visit us at&nbsp;www.acadia-pharm.com&nbsp;and follow us on&nbsp;LinkedIn&nbsp;and&nbsp;Twitter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forward-Looking
Statements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but
are not limited to statements regarding the timing of future events. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially
from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization. For a discussion of these and other factors, please refer to Acadia&#146;s
annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended&nbsp;December 31, 2020&nbsp;as well as Acadia&#146;s subsequent filings with the&nbsp;Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and Acadia undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Contact: </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acadia Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deb Kazenelson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(818) <FONT STYLE="white-space:nowrap">395-3043</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@acadia-pharm.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Contact: </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acadia Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Johnson, CFA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858) <FONT STYLE="white-space:nowrap">261-2771</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@acadia-pharm.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>acad-20211206.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 12/7/2021 12:42:06 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  xmlns:acad="http://www.acadia-pharm.com/20211206"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"

  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.acadia-pharm.com/20211206"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />

    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20211206_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20211206_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>acad-20211206_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 12/7/2021 12:42:06 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>acad-20211206_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 12/7/2021 12:42:06 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acad-20211206.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g257158g01j23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g257158g01j23.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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M^FV\?[R:V3/EW48[R1Y/_;.O5/A9\9O#GQA\/0ZAX>UBUU2WDC!)CD_>1_\
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:@ V4;*** #91LHHH -E"K@T44 .HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d257158d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acad-20211206.xsd" xlink:type="simple"/>
    <context id="duration_2021-12-06_to_2021-12-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070494</identifier>
        </entity>
        <period>
            <startDate>2021-12-06</startDate>
            <endDate>2021-12-06</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2021-12-06_to_2021-12-06"
      id="Hidden_dei_EntityRegistrantName">ACADIA PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2021-12-06_to_2021-12-06">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-12-06_to_2021-12-06"
      id="Hidden_dei_EntityCentralIndexKey">0001070494</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-12-06_to_2021-12-06">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-12-06_to_2021-12-06">2021-12-06</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-12-06_to_2021-12-06">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-12-06_to_2021-12-06">000-50768</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-12-06_to_2021-12-06">06-1376651</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-12-06_to_2021-12-06">12830 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2021-12-06_to_2021-12-06">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-12-06_to_2021-12-06">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-12-06_to_2021-12-06">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-12-06_to_2021-12-06">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-12-06_to_2021-12-06">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-12-06_to_2021-12-06">558-2871</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-12-06_to_2021-12-06">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-12-06_to_2021-12-06">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-12-06_to_2021-12-06">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-12-06_to_2021-12-06">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-12-06_to_2021-12-06">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-06_to_2021-12-06">ACAD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-06_to_2021-12-06">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-12-06_to_2021-12-06">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140485311714952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACADIA PHARMACEUTICALS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  06,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1376651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12830 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">558-2871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACAD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  **AE,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  "BH939>[[S>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>*'8@!Y/FLK)3"X,5-G8SMMJ:Q8FQ-9*^_1RO31G; ^QHZ?>G
M3Z!6>ZG'@,]A]!C(8GR873]$J?V&G8F\!(CZC$[%,B6&U#R.P2E*SW "K_2'
M.B&(JFK (2FC2,$"+/Q*9%UKM-0!%8WABC=ZQ?O/T&>8T8 ].APH B\YL&Z9
MZ"]SW\(=L, (@XO?!30K,5?_Q.8.L&MRCG9-3=-43G7.I1TXO.UW+WG=P@Z1
MU* Q_8I6TL7CAMTFO]:/V\,3ZT0E>,%%434'(21O9%6_+ZX__.[";C3V:/^Q
M\4VP:^'7771?4$L#!!0    (  **AE.97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M=B'9.2-Y[.8+7PLK"IU_9@FOZRJNXP?^>.J3V6?_Y<D/)M\6T\!_G)/I<X!
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M4$L! A0#%     @  HJ&4V7N^\WM    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @  HJ&4YE<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  "BH93O,'6HE<$  #L$   &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @  HJ&4Y^@&_"Q @  X@P
M  T              ( !F0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  "
MBH93EXJ[',     3 @  "P              @ %U#P  7W)E;',O+G)E;'-0
M2P$"% ,4    "  "BH93'#AEZC\!   \ @  #P              @ %>$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @  HJ&4R0>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @  HJ&4V60>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d257158d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d257158d8k.htm">d257158d8k.htm</File>
    <File>acad-20211206.xsd</File>
    <File>acad-20211206_lab.xml</File>
    <File>acad-20211206_pre.xml</File>
    <File>d257158dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d257158d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d257158d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acad-20211206_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acad-20211206_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "acad-20211206.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "acad",
   "nsuri": "http://www.acadia-pharm.com/20211206",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d257158d8k.htm",
      "contextRef": "duration_2021-12-06_to_2021-12-06",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d257158d8k.htm",
      "contextRef": "duration_2021-12-06_to_2021-12-06",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20211206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-21-349137-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-349137-xbrl.zip
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M8O!RO&.I7)KV!3**+,9=#IKW-Q^W-ORYQT6(Q?D?TK;]U/\,M)Y]>._G&C7
M+V[&Y[MOD.450AR]UTI7BY;HJ6:-OZGZ_Q-5?E%(;W&.U66J0"T"@7?-&-6_
M/4E]2;2G6G+\[A.AA+/4__"SL+<P7%)50FL.!O:.R*:13?N-Y>7?ZCBL&96L
MD<O =^!.8Q=P,V5/1ZZ8;<=UNWW2^E8FF[W<[0Q[OMUJ9PZ^_@]02P,$%
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M?["-<AD<I.9.%Y@7<K=GS(=YO527_ E02P,$%     @  HJ&4P,3:S5(%0
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M6H[E%F*][=R!10N?A$X?3E;:P'6Z]]^21X "3(+$01+EJF>[B#TA_!X%!$0
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MQ9!<T)%.]9ZJ>(7"J]<^K'88?_RA7JV702- M3.P#]!<R$<BHGX!#Z."RJ]
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MW:;+0K*B/K?GSHLAZH1 3>GT,E=I: [=])A>J32I&0R@>VQ _;X)[Y+P,RF
M(54<0!W='$S.0.CEAC^GZ[G2V9Q'=77J2>[B?CY^M=].+3YV]&K_I-7F/.-E
M)^"55/XN1]UV<]6>U_+4*E;6Q;6/.(0;HNK-%_D_Q^:CE#YF]/7[9:O_4F7?
MSILPO^[A-58OFWR;L-L9:I\FC5?M[UGQX>)FXQT-:DF52#-6$;A@YT7R,Q^^
M^E&M[T=_?4,079BR]^GZ9EI>.5VS*RW_E[NX%,&4_G'*PO0R,_P9",7\)-:B
MP_ $_5C)(KTO=+L(Z+2D?X_V5/]:[=E_ 5!+ P04    "  "BH93*)*=FIT5
M  "'2@  $0   &0R-3<Q-3AD97@Y.3$N:'1M[5QK4]M(UO[N*O^'+K9F"ZIL
MQ\;<0ZB7 $D\0P(;R%S>K?W0EMIV!TFM44MVG%^_SSG=DB\XP$R V;?>G9HJ
MP%9WGS[7YUR4PW?7[\^/#M^='9\>U6N'U[WK\[.CLU^;^_NMSN$+]R<^?^$?
M$(>O+TY_$Z_?GER<7WQ\M?;+N][UV1I](>HU/'>BDEQE1X>GO9_%U?5OYV>O
MUB8ZS$<'>ZUMG:P)&>EA\FHM4H.<5QU>EH_%,AOJI)F;]*"=YB^%_[MO\MS$
M[J.!2?*FU5_506?V]T#&.IH>7.M86?%!3<1'$TN<='S>>_OAU5JFAR,<=?CZ
MZ.S+2/=U+NAFXO#%ZZ/#%Y='<P3,[;Z)W9?HN47.VM'?D[Y-7](NN/BW[K%B
M'3$**WKOWXJKCR>OUH:;V[N=[;UAN_-YL]OZG Z)^.M7:^<7;R\<DQ8)G3N!
M*7TL5@4L.^;5<2!#+<7E2&:Q#%21ZT!&5APGB2F2 *LOC=6Y'BMQ^.;BPW4E
MZI'.5=.F6'*0F$DFT[6C:Y,V(YVHPQ?TY)'XJ&P1Y58,,A/7:_E(B4L]-KF,
MZ#2K1'>5;)Y(.>9N?"['*@E5)JXS#5K, +^8 >C.=:B$3D!WGHNK:1*";E71
M^ W)/XU<>D?-!:IBE=_/_\ TTTR#E&DI 3480)S!5.#"J=$)A!&JV"0VSV2N
MDZ&P.7Y:EGDT%186JVE%D@L=IYD9JQ@4U6OX)1-IA,/ZACA$LESDTFLUDF-M
MBDS\HU#8T"2)U)D2ZQ^O7O]C0ZRGK]JM=F=W>T/().3U)U 5.E>\C4P?/WHX
M4%F+E222WNSX^R^^?O*VU^QME+=VA[6[[0T(K_>?(;P;!?:JP"0AQ%.)X\](
M0RP) U>[CS_W/G!R]?JJ>7K9[%U['E8_>D=__UMGN_T2E[HR =F+Y^[.UD9#
M!#)30TWT6-"L2'"RKR.=3T5N1&#BN" 9YXH%(?X22=Q[^<M,-;%'J3VG63$4
MQVD:$>&DC;%2+)V)SD>LN9]:5RWQYO28A) D*@1-&7\QT)G-Q>^%S'"\V&QO
M;OYU"GABDH'*%%RX('5BLYNH?B!!(6335V*D(EBB">54R%QL'73;(FW%+7&&
M1U26"#KF6>@GIWQU_$&<]L[>7@C2M\Y+<:H"%?=5YD+O3H/8V1%>&>&2Q3<"
M5R\)6F[-^@=I0_G[@3@^.3[=*&_JXUHH4A_7'F _^5)@R^8"&PL^=7&M406V
M,L8<7GU:@3KVMG]X*6 U3'*3@=(!SEAC6^OB>EAU] >7"K?*YD4(_S*64>%\
M"I%7A0%2 BL'"O9I!@C)BW&OL[<KACH#$^FY*?@$I8=S3X0<@F'WLFF[N=DN
M6315,K/.9#A06!\H6N)Z]  HT=EL3I2Z*7?SWJX)_PF:HPC4N(O._"<^DG\J
MG)'Q0G-'?RJ^EF&U)2[^>%2$_QS)9*B<'O6A.:1D9)UT=]'9%!-I[R>KN4WX
MW1$T!B5N0;UVUY).:W<Q6B(TOR0]40%D!47#9]W=#2>M;T=J9X[?$ZMM8, /
M^)_Y*W=;VWR3;FMO%LR7R=LJR2->"@VEK==F\4A:"Q)=O!RP9/@@.XU3^"A+
M'R[H905+[H^51'])/ATKAHXMZ6AJ-4)DLG3XQ&16)62+T#2GA_S'8-DRGMS/
M'H>A)B4DZVB(>>M_L!U9E<K,Q<4%*S)._5?#G(8#?!4<H-7$[ZMIW#>(L_6:
M-Y1,7!&.L/#^8Q69E%A(Z0)1&JGO<*8("P.0W[PV81B![).1"FXB7-%IL(<V
M "P<%913R\= 5NLS:#5_U,8BSGHD1]!>Y0CN=@.=)="\L_6R7ELRM.Y&ZZD3
M4Q+6UNY+F#/")XP8JA/ ;<HA64H5;J$?*;1'41Y#^L.;:6PDF6"H;G^Z;%27
MY8),I2:C9^9"@:6PYT1=>H:&B/2- CZBDV4_8C& @M20@S PCF!D-%#59$2!
MT=ZX4Z'@FJC+:-<&6;KZDJH,1P>T44S.9Y I%4+ %6P 23 _3JY'=)^X(BL?
MP24&F2+H;/HPQX"L L0B4)%WPS?6.S8<&V$'VR 6[KU$?->A^!$BS&"+YRTP
MN0 P>=\Z;1$\X1]([L$D7/H*>@?69>+,WF@0<#)">&+6GB),!;G)&N)G24 &
MJ#X7/RF"NU/A2C\OV2[AZ'!9D'*I ,?R3 >X_JD>ZS*3P_D(V68X;918S?_%
M'B!5;'EG8>'\PL)YGQ+RY9;2B??8G4*0.YK75GF\@P(Z&5.('4I0W1*5/E4X
MKWH>LN8%I5K9(B7-@&13DV-[HB<GUK,#)Z6['2D@.2RG[^'NH5!8S]XQ5RFM
MF,@L)&G),.1(R3@,L2(CU680!M4PA16)9P[?+=068E4M+\@G#P=7S(;957$^
M 2R=%,Y%4S0@NXDX*D#W9X]"3;,A7S\D"<%>QZRWZ]=GQV=V WX+%^WLMC9_
M*,L%\]%FF)DBA>VPPP5+>//-5J=\N%XKPPH_Z<)\;)"Y4$I)P6/Q5#X-VI=E
M(R7%^EZ[M?.#3]?F3B67V-FG4_@K?P10&,7HD0Y&8G^WU5U),-36'0)[R20\
M3086(U#:QP@1$$X(J39C ^4$JQM+L8'T96QBS7!^?7.GM?^-R^U7UUYUMYV_
M_F:MI9MY#7]QVOL9G_F"<KTF^/_#%.8TC=2BXJOXEM[31RDRE&8?ZGG3["L8
MH#J0T41.+155#]]]%%>]_P6-W;5R2ZYI'_QMG_];$[_T3J_?O5KKM-L_5-GT
MR=F'Z[./_XD%;VQ^Y?W'*D- O%#96+$#ZI(%0@><QX.M 27I5/K(QVG/+8V
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M((1%5?Q%-(MO"4DVQ&0R:4G^JIF2^VW!D39*;KC2FP%[@,RKZK[,@I&F/+0
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M<W>W\UPZI[/5"K?:;1^^H'])"A_R/T#U;U!+ 0(4 Q0    (  **AE,J?UH
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M-3<Q-3AD.&LN:'1M4$L! A0#%     @  HJ&4RB2G9J=%0  ATH  !$
M         ( !J20  &0R-3<Q-3AD97@Y.3$N:'1M4$L%!@     %  4 0 $
' '4Z      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
